Bishop 1967.

Methods	Allocation: "prearranged randomised procedure". Blindness: double (identical capsules in individual bottles labeled with the subjects' study number). Design: 2 parallel groups, single centre. Duration: 6 weeks (preceded for 2 weeks washout). Analysis: intention‐to‐treat described only for side effects and use of antiparkinson agents. Country: USA.
Participants	Diagnosis: schizophrenia, no further information. N=52. Age: range 19‐51 years, mean 30.8 years. Sex: M 15, F 37. Setting: hospital. History: first admission, or no more than 2 hospitalisations with good remissions.
Interventions	1. Trifluoperazine: range 7.5‐30 mg/day. N=27. 2. SK&F 14336 (acridanes) range 100‐400 mg/day. N=25.
Outcomes	Global state: (CGI). Leaving the study early. Side effects. Use of antiparkinson agents. Unable to use ‐ Mental state: (BPRS ‐ only "p" value). Behaviour: (NOSIE ‐ only "p" value). Laboratory tests ‐ no data. Vital signs ‐ no data.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear